Sonire Therapeutics: Valuation, Funding & Investors
Sonire Therapeutics is a U.S.-based clinical-stage medical device company developing non-invasive high-intensity focused ultrasound (HIFU) sonic therapies for cancer, with a particular focus on pancreatic cancer. The company is advancing anesthesia-free, outpatient treatment options and progressing U.S. clinical programs and regulatory pathways following an FDA Breakthrough Device Designation.
Leadership & Board
- Current Number of Employees
- 7
- Current LinkedIn Followers
- 807
Latest Estimated Valuation
- Total Amount Raised
- $18M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $18M
- Latest Funding Round
- Series A
Employee Trend
Sonire Therapeutics had 7 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
7Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Sonire Therapeutics had 807 followers as of November 9, 2026. The number of followers increased by 1 (0.12%) week-over-week.
807Latest Followers Count
1(0.12%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Apr 15, 2026 | Series A | $18.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Santé Ventures | Series A |
| Fast Track Initiative, Inc. | Series A |
| Nomura SPARX Investment | Series A |
Similar Companies
Related News and Analysis
